US equities |
MU $1,057.16 ▲+1.11% NVDA $237.87 ▼-0.57% SNDK $1,699.75 ▲+2.37% AMD $638.92 ▼-1.62% INTC $114.22 ▲+1.52% SPCX $168.19 ▼-2.17% TSLA $376.19 ▼-1.18% MRVL $283.25 ▼-1.31%
FinancialContent

Soligenix, Inc. - Common Stock (NQ:SNGX)

0.3606 +0.0026 (+0.73%)
Delayed Quote Updated: 10:35 AM EDT, Oct 7, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Soligenix, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
15 16 Next >
Which stocks are moving on Wednesday? ↗
Via Chartmill
Here are the top movers in Wednesday's session. ↗
Via Chartmill
Which stocks are gapping on Wednesday? ↗
Via Chartmill
These stocks are moving in today's pre-market session ↗
Via Chartmill
Keep an eye on the top gainers and losers in Wednesday's session. ↗
Via Chartmill
Most active stocks in Wednesday's session ↗
Via Chartmill
Wednesday's session: top gainers and losers ↗
Via Chartmill
Let's uncover which stocks are experiencing notable gaps during today's session. ↗
Via Chartmill
Which stocks are moving before the opening bell on Wednesday? ↗
Via Chartmill
Curious about the stocks that are showing activity after the closing bell on Tuesday? ↗
Via Chartmill
These stocks have an unusual volume in today's session ↗
Via Chartmill
Wednesday's session: top gainers and losers ↗
Via Chartmill
On Wednesday, there are stocks with unusual volume. Let's take a look. ↗
Via Chartmill
Here are the top movers in Tuesday's session. ↗
Via Chartmill
Which stocks are experiencing notable movement on Tuesday? ↗
Via Chartmill
Gapping stocks in Tuesday's session ↗
Via Chartmill
Top movers in Tuesday's pre-market session ↗
Via Chartmill
BioMedNewsBreaks — Soligenix Inc. (NASDAQ: SNGX) CEO Highlights Capital Discipline as Critical to Biotech Success in Pharmaphorum Analysis
Via Investor Brand Network
BioMedNewsBreaks — Soligenix Inc. (NASDAQ: SNGX) Highlights Patient-Centric Drug Development Strategy Through Reformulation Approach
Via Investor Brand Network
Soligenix Inc. (NASDAQ: SNGX) Strengthens Pipeline as European Commission Grants SGX945 Orphan Status
Via Investor Brand Network
Soligenix Inc. (NASDAQ: SNGX) Advances CTCL Research with Interim Analysis, Comparative Study Results
Via Investor Brand Network
Soligenix Inc. (NASDAQ: SNGX) Gains Analytical Validation as Pipeline Progress Drives Forward Outlook
Via Investor Brand Network
MissionIRNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) Showcased for Smarter Path to Drug Development
Via Investor Brand Network
News headline image
BIO-key International, 20/20 Biolabs, Society Pass, and Soligenix Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
Via ACCESS Newswire
BioMedNewsBreaks — Soligenix Inc. (NASDAQ: SNGX) Publishes Positive HyBryte Study Results In Oncology and Therapy
Via Investor Brand Network
Soligenix Inc. (NASDAQ: SNGX) Advances Clinical Credibility with HyBryte Research Publication
Via Investor Brand Network
Soligenix Inc. (NASDAQ: SNGX) Expands Pipeline Momentum as SGX945 Earns Global Recognition
Via Investor Brand Network
BioMedNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) Highlights Phase 3 CTCL Progress and Orphan Drug Milestones in 2025 Results
Via Investor Brand Network
BioMedNewsBreaks — Soligenix Inc. (NASDAQ: SNGX) Receives EU Orphan Drug Designation For Dusquetide In Behçet Disease
Via Investor Brand Network
Soligenix Inc. (NASDAQ: SNGX) Spotlighted in Recent Zacks Research Report as Key Clinical Milestones Approach
Via Investor Brand Network
< Previous 1 2 3 4 5 6 7 8 9
...
15 16 Next >